Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, showing improved liquidity, lower operating expenses, and progress in its clinical development program. The company’s cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, for combined holdings of $12.22 million, compared with $4.12 million at year-end 2025, excluding restricted digital assets. Shareholders’ equity increased 91% to $9.77 million, and working capital rose to $5.47 million from $420,000.
Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million. The company also reported a 21% reduction in operating cash use for the first nine months of 2026 and a decrease in notes payable to $300,000 following repayment of $1 million in debt. Management stated that its cash and digital asset holdings are sufficient to support planned operations over the next 12 months.
Following quarter-end, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. The agreement follows U.S. Food and Drug Administration clearance of the company’s Investigational New Drug application in August 2026. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The start-up agreement with Thermo Fisher’s clinical research business marks a key step toward executing the Phase 2 trial, which is necessary to evaluate the compound’s safety and efficacy in patients.
The financial improvements and clinical progress are detailed in the full press release available at https://ibn.fm/GJ1ER. For investors, the strengthened balance sheet and reduced cash burn extend the company’s runway and provide funding to advance Lucid-MS without immediate dilution. For the biotech industry, the move into Phase 2 testing for a progressive multiple sclerosis candidate highlights continued innovation in neurodegenerative research, where treatment options remain limited. The company’s digital asset holdings, which now represent a substantial portion of its liquidity, also reflect a growing trend among small-cap biotechs to diversify treasury reserves.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. The company also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty rights of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
For more information about Quantum BioPharma, visit Quantum BioPharma (NASDAQ: QNTM). The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.

